Opinion
Video
Author(s):
Panelists discuss how to determine appropriate second-line and subsequent therapies for unresectable hepatocellular carcinoma after frontline treatment, emphasizing patient-specific factors and alternatives to clinical trial enrollment.
Video content above is prompted by the following:
Dr El-Khoueiry/Dr Kudo: After frontline therapy in unresectable hepatocellular carcinomauHCC, how do you determine the appropriate second- line and beyond therapy?
• What patient-specific factors do you consider?
• Other than clinical trial enrollment, what would you consider for second-line2L treatment?